Identification in several human myeloid leukemias or cell lines of a DNA rearrangement next to the c-mos 3&#x0301;-end  by Revoltella, Roberto P. et al.
Volume 189, number I FEES 2848 September 1985 
Identification in several human myelaid leukemias or cell 
lines of a DNA rearrangement ext to the c-mos 3’-end 
Roberto P, Revoltella, Morag Park and Alberta Fruscalzo* 
A characteristic DNA ~~gement, the loss of an EcoRi cleavage site next to the 3’-end of the human 
c-mos gene, has been found to be frquentiy present in DNA from &ansformed hematopoietk cells of the 
myeloid lineage but not in DNA from either normal or transformed cells of different tissue types. T&e 
established cell lines, respectively apro-monocytic line (CM-S) and two precursor granulocytic lines (My/K1 
and My/KS), carry the same genome rearrangement, but not fibroblasts obtained from the marrow of the 
same patients. This DNA rearrangement is maintained in three different hybridomas derived by fusion of 
CM-S cells with normal human embryo hepatwytea. 
Proto-oncogem c-mos DNA rearrangement 
The association between certain human 
neoplasias and characteristic hromosomal abnor- 
malities or genome rearrangements [1,2] with 
cellular oncogenes has suggested the possibility of 
the involvement of oncogenes in these recombina- 
tions and a possible role that they may play in pro- 
ducing various types of derangements in the struc- 
ture and function of other cellular gene sequences 
during the multistep evolution of fully malignant 
tumors. e-mof is a cellular oncogene which 
possesses the potential to become malignant 
through incorporation in the genome of 
retroviruses (31 or undergoing alteration within the 
cell [4]. The coding region of c-mos and v-mos 
[S,6] has been identified. The human c-mos has 
been mapped in the q22 region of chromosome 8 
t71. 
In the course of experiments aimed at examining 
the arra~ements of c-mos sequences in the 
genome of human cells from different tissue origin 
or types, we have identified a characteristic DNA 
r~rrangement next to the 3’ -end of the c-mos 
gene. This genome alteration has been found to be 
frequently present in DNA from transformed 
hematopoietic ells of the myeloid lineage. 
2. MATERIALS AND METHODS 
DNA samples were obtained from peripheral 
blood leukocytes of 19 normal volunteers, 15 pa- 
tients with chronic lymphoid leukemia (CLL), f2 
with acute lymphoblastic leukemia (ALL), 9 with 
acute, myelo-monoc~i~ leukemia (M4), 8 with 
acute’monocytic leukemia (MS), and 12 with acute 
myeloblastic leukemia (Ml) fS] . DNA was also ob- 
tained from 4 Iymphoma tumors, 6 hepatomas, 5 
lung carcinomas, 6 melanomas, 4 gliomas and nor- 
mal human placenta. We also examined DNAs ob- 
tained from a number of established human cell 
lines, including 2 melanoma, 1 teratocarcinama, 5 
different EBV-infected lymphoblastoma cell lines, 
the 2 myeloid K-562 and HL-60 cell lines, the pro- 
monocytic CM-S line and the fibroblast CM/F3 
line, both isolated from Ihe bone marrow of a pa- 
tient with congenital hypopiastic anemia (syn- 
drome of Diamond-~la~kf~) [9,10], and 2 
myeloid cell lines (My/K1 and My/Kg) and 2 
~brobl~to~d-like cell lines (FB-Kl and FB/KS), 
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recently isolated in this laboratory from the mar- 
row of 2 patients with M4. DNAs were cleaved 
with specific endonucleases, electrophoresed 
through a 1% agarose gel, blot hybridized by the 
Southern procedure [ 1 l] with a 32P-labelled probe, 
as specified in the text, and radioautographs of the 
filters were made. 
3. RESULTS AND DISCUSSION 
Souther transfers containing EcoRI-digested 
DNAs from 2 patients with M5 and 3 with M4 
when hybridized with an AvaI-SmaI specific frag- 
ment probe from human c-mos revealed that in ad- 
dition to the expected mos specific EcoRI fragment 
of 2.4 kb, there was an additional EcoRI fragment 
of 5.5 kb. The results of a representative xperi- 
ment are shown in fig.1. The same results (see ex- 
ample in fig.2, lower right) were obtained with 
DNAs from the CM-S cell line and with 2 other 
myeloid lines, My/K1 and My/KS, but not from 
marrow fibroblasts of the same patients. None of 
the other DNAs revealed any evidence of a similar 
mos hybridization pattern. The same radiolabelled 
mos probe hybridized with either the expected mos 
specific restriction fragments in HindIII, KpnI or 
BglII-digested DNAs from all DNA preparations 
(not shown). This suggested that no gross rear- 
rangement had occurred within the mos gene. We 
therefore examined the possibility that a small gene 
alteration had resulted in the loss of the EcoRI site 
either 5 ’ or 3 ’ to the mos locus, generating an 
EcoRI-restriction fragment length polymorphism 
(RLFP) which is detected by this probe. To deter- 
mine whether this RFLP was generated by loss of 
the EcoRI site immediately 5 ’ to the mos coding 
region (see fig.2, upper) a KpnI-XbaI fragment 
(fragment II) which maps 5 ’ to this EcoRI site was 
used to rehybridize the same blot after removal of 
the previous probe. With loss of this 5 ’ -EcoRI site 
one would expect both fragments I and II to 
hybridize to the same EcoRI restriction fragment. 
However, fragment II hybridizes only in the ex- 
pected EcoRI restriction fragment of 3.0 kb, sug- 
gesting that the EcoRI site 3 ’ to the mos gene must 
be altered (fig.2, lower left). 
The availability of the 2 CM-S and CM/FB 
lines, which both derive from the same CHA pa- 
tient but only one (CM-S) carries the gene rear- 
rangement next to the c-mos 3 ‘-end, offered a con- 
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Fig. 1. Southern blot analysis of mos sequence in EcoRI- 
digested DNA from normal human placenta (a), 
peripheral blood leukocytes of a patient with M4 (b) and 
2 patients with MS (c,d). High-M, DNA (1Opg) was 
digested with the restriction enzyme, size fractionated on 
0.7% agarose gel, and transferred to a nitrocellulose 
filter. Hybridization with the 32P-labelled c-mos (an 
AvaI-SmaI fragment contained in the plasmid BR322) 
was in 10% dextran sulfate containing 50% formamide. 
Size markers indicate that bands were 2.4 and 5.5 kb, 
respectively. 
venient system to examine the persistence of this 
rearrangement. Although the CM-S line derived 
from a non-neoplastic patient, these cells under- 
went spontaneous malignant transformation in 
vitro, with successive passage of the cells in liquid 
culture [12]. CM-S cells retained an euploid 
karyotype for over 100 continuous passages and 
during this period they consistently failed to form 
colonies in agar and to give rise to tumors when in- 
oculated into athymic mice. On prolonged culture, 
however, CM-S cells gradually acquired non- 
random chromosome abnormalities and became 
tumorigenic in these hosts. Conversely, CM/FB 
cells remained euploid and consistently failed to 
form colonies in agar or tumors in mice [10,13]. 
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Fig.2. Physical map of the human c-mos locus coding region (upper), represented by the dashed bar. The strategy used 
to determine the structure and hybridization pattern of c-mos in the DNA preparations tested is shown. Black bar I 
delineates fragment I, an AvaI-SmaI fragment in the c-mos locus and black bar II a KpnI-XbaI fragment near the 5 ‘-end 
of the c-mos gene. After EcoRI cleavage, upon hybridization with the 32P-labelled probe (lower right) CM/FB DNA 
(a) reveals a single fragment of 2.4 kb, while respective DNAs from the pro-monocytic cell line CM-S (b), 2 myeloid 
lines My/K1 (c) and My/KS (d) show an additional, identical fragment of 5.5 kb. After removal of the previous probe, 
the same DNA transfers were re-hybridized with the 32P-labelled fragment II: all DNAs hybridized at the same expected 
3.0 kb fragment (lower left). 
Fig.3 shows that after EcoRI cleavage, DNA from 
euploid CM-S cells of the early passages or 
aneuploid, malignant cells of the late passages, 
showed 2 bands of hybridization with fragment I. 
Interestingly, the additional 5.5 kb band appeared 
more intense than the normal 2.4 kb band with 
DNA from cells of the late passages, as compared 
to DNA from cells of the early passages. With 
DNA obtained from different cell preparations, we 
have consistently observed this difference in inten- 
sity between the normal and additional band, sug- 
gesting that this rearrangement sequence may have 
undergone amplification. It is worthy of note that 
this increased intensity of hybridization shown 
with DNA from CM-S of the late passages cor- 
related with the prevailing in culture of a clone of 
cells carrying trisomy of chromosome 8 [ 10,131. 
Hybrids were also made by fusion (with PEG) [ 141 
between a hypoxanthine phosphoribosyltrans- 
ferase (HPRT) deficient clone of the late passage 
CM-S cells and human embryo hepatocytes in 
primary culture. Since the parental cells carried 
different histocompatibility (HLA . DR) antigens, 
enzyme and chromosome markers, hybrid clones 
isolated from agar in HAT-selecting medium could 
be easily identified (not shown). The results of a 
representative xperiment of hybridization by the 
Southern procedure between EcoRI-cleaved DNA 
with the radiolabelled fragment I are shown in 
fig.4. We demonstrate here that the same DNA 
rearrangement downstream from the c-mos 
3 ’ -end, which is present in CM-S cells, was main- 
tained in 3 out of 12 hybridomas tested in this ex- 
periment. As expected, DNA from the parental 
hepatocytes hybridized the fragment I probe with 
a single 2.4 kb band. 
Poly(A)+ RNA preparations were obtained from 
CM-S cells of an early (56th) or late (314th) 
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a b c d e rearrangement detected in CM-S cells, but not in 
fibroblasts of the same Diamond-Blackfan patient, 
had any relevance in the generation and develop- 
ment of the transformed phenotype of CM-S cells 
remains unknown. 
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Fig.3. Southern blot analysis of c-mos sequence in 
EcoRI-digested DNAs from the CM/FB line (a) or the 
pro-monocytic CM-S line (passage 30, 156 and 290 at 
lane b-d, respectively). The 2.4 kb band represents the 
normal allele, while the 5.5 kb band represents the 
rearranged allele. The 5.5 kb band appears more intense 
than the normal 2.4 kb band with DNAs from CM-S 
cells of the later passage compared to DNAs from the 
earlier passages. 
passage as well as from CM/FB cells. 15 pg 
poly(A)+ RNA were analyzed by Northern 
hybridization [15], but no mos specific mRNA 
could be demonstrated. Whether the above gene 
12345678 
: 
In conclusion, we provide here evidence of a 
genome rearrangement resulting in the loss of an 
EcoRI cleavage site next to the 3’-end of the c-mos 
locus. This rearrangement appears to be not 
detected in a variety of normal tissues or cells of 
different types, nor to occur frequently in human 
disorders, except in certain myeloid leukemias. 
The same rearrangement has also been found in 3 
established cell lines, all committed along the 
monocytic-granulocytic pathway. Altered c-mos 
sequences have been reported infrequently. A rear- 
ranged c-mos locus has been recently demonstrated 
[ 16- 191 in murine plasmacytoma cell lines as well 
as in hybridomas. Activation of the c-mos gene 
was demonstrated in these cells and the altered 
gene transformed mouse fibroblasts in transfection 
experiments [161. Multiple c-mos rearrangements 
were demonstrated in these myeloma cells, but all 
probably arose by the insertion within or next to 
the c-mos coding region [17-191 of a portion of the 
LTR sequence of an endogenous intracisternal-A 
particle genome (IAP) [17]. The latter are non- 
infectious retrovirus-like structures found regular- 
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Fig.4. Southern blot analysis of c-mos sequences in DNA from primary cultures of normal human hepatocytes (l), an 
(HPRT-)clone of CM-S cells (2), and hybrids (3-12). High-M, DNAs were digested with EcoRI endonuclease, size 
fractionated on 0.7% agarose gel (lO/~g/lane) and transferred to a nitrocellulose filter. Hybridization with the 
radiolabelled c-mos fragment II probe was performed in 10% dextran sulfate containing 50% formamide. 
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ly in numerous copies in early mouse embryo 
[20-221, in plasmacytoma [23] or other mouse 
tumors [24]. IAPs seem to behave as movable 
elements with potential to alter profoundly gene 
expression either because they contain a transcrip- 
tional enhancer element [25] or because they 
change the structure of the chromatin and increase 
accessibility to enzymes participating in transcrip- 
tion [17]. More recently, Dr C.J. Larsen and his 
collaborators from the Hapital St. Louis in Paris 
have found an EcoRI-RFLP downstream from the 
c-mos 3 '-end in DNA of one patient with breast 
carcinoma (personal communication). Since 
suitable probes 3 ’ to the human c-mos coding 
region are not yet available, we are unable to con- 
firm whether the common DNA rearrangement 
that we have described above in human myeloid 
cells is due to a smalI deletion, base alteration or 
gene insertion. It could be associated with the 
organization and assembly of a cellular gene 
coding for a stage-differentiation protein of 
precursor myeloid cells. 
The cloning from CM-S and CM/FB cells of the 
two 2.4 and 5.5 kb sequences both hybridizing the 
c-mos specific probe, should allow the identifica- 
tion of this DNA rearrangement and clarify the 
significance of this event. 
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